Developing a new treatment for Sjögren’s syndrome using a CD40 antagonist.
Official title: Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
Funded at Boston Immune Technologies and Therapeutics, INC. · NIH-11228815 · Data updated 2026-11-12
This study is looking at a new treatment called BITT-101 for people with Sjögren’s syndrome, which can cause dryness and pain, and it aims to see if this treatment is safe and effective for helping manage your symptoms.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Immune Technologies and Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Winchester, United States) |
| Project start | August 21, 2023 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $926,858 |
| NIH project number | 4R44AI179385-02 |
| Project ID | NIH-11228815 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Sjögren’s syndrome who are experiencing significant symptoms and have not responded to existing treatments.
✕Less likely to help
Patients with other autoimmune disorders unrelated to Sjögren’s syndrome may not benefit from this research.
What this research studies
This research focuses on Sjögren’s syndrome, a debilitating autoimmune disease that causes dryness and pain due to the destruction of salivary and lacrimal glands. The study aims to advance BITT-101, a novel CD40 antagonist that targets a key pathway involved in B-cell activation, which has shown promise in preclinical models. By stabilizing the inactive form of CD40, BITT-101 seeks to block harmful interactions that can lead to severe complications. Patients may have the opportunity to participate in trials assessing the safety and efficacy of this innovative treatment.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from Sjögren’s syndrome.
How similar studies have gone: While targeting the CD40 pathway has shown promise in preclinical models, the approach with BITT-101 is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Boston Immune Technologies and Therapeutics, INC.
Winchester, United States Active
Researchers
- Principal investigator: Olivier, Kenneth — Boston Immune Technologies and Therapeutics, INC.
- Study coordinator: Olivier, Kenneth
Related research
Other NIH-funded projects on the same topics.
-
BITT-101: a new CD40 blocker for Sjögren’s syndrome
A new therapy called BITT-101 aims to block a key immune signal to help people with Sjögren’s syndrome who currently have limited treatment options.
-
New antibody treatment for Non-Hodgkin Lymphoma and a type of skin lymphoma
This project is testing a new antibody treatment, called BITR2101, for people with certain types of cancer, including Non-Hodgkin Lymphoma and Cutaneous T Cell Lymphoma.
-
New treatment targeting cancer cells and their supportive environment in Non-Hodgkin Lymphoma.
This study is testing a new treatment called BITR2101 that targets a specific part of cancer cells to help stop the growth of Non-Hodgkin Lymphoma, especially for those with Cutaneous T Cell Lymphoma, and it may be used on its own or with other therapies to improve patient outcomes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.